Literature DB >> 25970207

Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers.

Rashmi Jalah1,2, Oscar B Torres1,2, Alexander V Mayorov1,2, Fuying Li3,4, Joshua F G Antoline3,4, Arthur E Jacobson3,4, Kenner C Rice3,4, Jeffrey R Deschamps5, Zoltan Beck1,2, Carl R Alving1, Gary R Matyas1.   

Abstract

Vaccines against drugs of abuse have induced antibodies in animals that blocked the biological effects of the drug by sequestering the drug in the blood and preventing it from crossing the blood-brain barrier. Drugs of abuse are too small to induce antibodies and, therefore, require conjugation of drug hapten analogs to a carrier protein. The efficacy of these conjugate vaccines depends on several factors including hapten design, coupling strategy, hapten density, carrier protein selection, and vaccine adjuvant. Previously, we have shown that 1 (MorHap), a heroin/morphine hapten, conjugated to tetanus toxoid (TT) and mixed with liposomes containing monophosphoryl lipid A [L(MPLA)] as adjuvant, partially blocked the antinociceptive effects of heroin in mice. Herein, we extended those findings, demonstrating greatly improved vaccine induced antinociceptive effects up to 3% mean maximal potential effect (%MPE). This was obtained by evaluating the effects of vaccine efficacy of hapten 1 vaccine conjugates with varying hapten densities using two different commonly used carrier proteins, TT and cross-reactive material 197 (CRM197). Immunization of mice with these conjugates mixed with L(MPLA) induced very high anti-1 IgG peak levels of 400-1500 μg/mL that bound to both heroin and its metabolites, 6-acetylmorphine and morphine. Except for the lowest hapten density for each carrier, the antibody titers and affinity were independent of hapten density. The TT carrier based vaccines induced long-lived inhibition of heroin-induced antinociception that correlated with increasing hapten density. The best formulation contained TT with the highest hapten density of ≥30 haptens/TT molecule and induced %MPE of approximately 3% after heroin challenge. In contrast, the best formulation using CRM197 was with intermediate 1 densities (10-15 haptens/CRM197 molecule), but the %MPE was approximately 13%. In addition, the chemical synthesis of 1, the optimization of the conjugation method, and the methods for the accurate quantification of hapten density are described.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25970207      PMCID: PMC4472500          DOI: 10.1021/acs.bioconjchem.5b00085

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  45 in total

1.  Synthesis and characterization of hapten-protein conjugates for antibody production against small molecules.

Authors:  K V Singh; Jasdeep Kaur; Grish C Varshney; Manoj Raje; C Raman Suri
Journal:  Bioconjug Chem       Date:  2004 Jan-Feb       Impact factor: 4.774

2.  Understanding chemical reactivity for homo- and heterobifunctional protein cross-linking agents.

Authors:  Fan Chen; Simone Nielsen; Renato Zenobi
Journal:  J Mass Spectrom       Date:  2013-07       Impact factor: 1.982

3.  Dynamic vaccine blocks relapse to compulsive intake of heroin.

Authors:  Joel E Schlosburg; Leandro F Vendruscolo; Paul T Bremer; Jonathan W Lockner; Carrie L Wade; Ashlee A K Nunes; G Neil Stowe; Scott Edwards; Kim D Janda; George F Koob
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-06       Impact factor: 11.205

4.  Applications and recent developments of multi-analyte simultaneous analysis by enzyme-linked immunosorbent assays.

Authors:  Hongyan Zhang; Shuo Wang; Guozhen Fang
Journal:  J Immunol Methods       Date:  2011-03-01       Impact factor: 2.303

Review 5.  Comparative effects of carrier proteins on vaccine-induced immune response.

Authors:  Markus Knuf; Frank Kowalzik; Dorothee Kieninger
Journal:  Vaccine       Date:  2011-05-05       Impact factor: 3.641

6.  Synthesis and biological evaluation of some 6-arylamidomorphines as analogues of morphine-6-glucuronide.

Authors:  James M Macdougall; Xiao-Dong Zhang; Willma E Polgar; Taline V Khroyan; Lawrence Toll; John R Cashman
Journal:  Bioorg Med Chem       Date:  2004-11-15       Impact factor: 3.641

7.  Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats.

Authors:  M D Raleigh; M Pravetoni; A C Harris; A K Birnbaum; P R Pentel
Journal:  J Pharmacol Exp Ther       Date:  2012-12-07       Impact factor: 4.030

Review 8.  Can you vaccinate against substance abuse?

Authors:  Thomas R Kosten; Coreen B Domingo
Journal:  Expert Opin Biol Ther       Date:  2013-04-18       Impact factor: 4.388

9.  A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents.

Authors:  Benito Anton; Philippe Leff
Journal:  Vaccine       Date:  2006-02-08       Impact factor: 3.641

10.  Identification of formaldehyde-induced modifications in proteins: reactions with model peptides.

Authors:  Bernard Metz; Gideon F A Kersten; Peter Hoogerhout; Humphrey F Brugghe; Hans A M Timmermans; Ad de Jong; Hugo Meiring; Jan ten Hove; Wim E Hennink; Daan J A Crommelin; Wim Jiskoot
Journal:  J Biol Chem       Date:  2003-11-24       Impact factor: 5.157

View more
  34 in total

Review 1.  Development of vaccines to treat opioid use disorders and reduce incidence of overdose.

Authors:  Marco Pravetoni; Sandra D Comer
Journal:  Neuropharmacology       Date:  2019-06-04       Impact factor: 5.250

2.  Heroin vaccine: Using titer, affinity, and antinociception as metrics when examining sex and strain differences.

Authors:  Candy S Hwang; Lauren C Smith; Cody J Wenthur; Beverly Ellis; Bin Zhou; Kim D Janda
Journal:  Vaccine       Date:  2019-06-05       Impact factor: 3.641

Review 3.  Conjugate Vaccine Immunotherapy for Substance Use Disorder.

Authors:  Paul T Bremer; Kim D Janda
Journal:  Pharmacol Rev       Date:  2017-07       Impact factor: 25.468

4.  Enhancing Efficacy and Stability of an Antiheroin Vaccine: Examination of Antinociception, Opioid Binding Profile, and Lethality.

Authors:  Candy S Hwang; Paul T Bremer; Cody J Wenthur; Sam On Ho; SuMing Chiang; Beverly Ellis; Bin Zhou; Gary Fujii; Kim D Janda
Journal:  Mol Pharm       Date:  2018-02-19       Impact factor: 4.939

Review 5.  Biologics to treat substance use disorders: Current status and new directions.

Authors:  Marco Pravetoni
Journal:  Hum Vaccin Immunother       Date:  2016-07-21       Impact factor: 3.452

6.  Effectiveness and selectivity of a heroin conjugate vaccine to attenuate heroin, 6-acetylmorphine, and morphine antinociception in rats: Comparison with naltrexone.

Authors:  Kathryn L Schwienteck; Steven Blake; Paul T Bremer; Justin L Poklis; E Andrew Townsend; S Stevens Negus; Matthew L Banks
Journal:  Drug Alcohol Depend       Date:  2019-08-24       Impact factor: 4.492

7.  Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex.

Authors:  Zoltan Beck; Oscar B Torres; Gary R Matyas; David E Lanar; Carl R Alving
Journal:  J Control Release       Date:  2018-02-09       Impact factor: 9.776

8.  Combatting Synthetic Designer Opioids: A Conjugate Vaccine Ablates Lethal Doses of Fentanyl Class Drugs.

Authors:  Paul T Bremer; Atsushi Kimishima; Joel E Schlosburg; Bin Zhou; Karen C Collins; Kim D Janda
Journal:  Angew Chem Int Ed Engl       Date:  2016-02-16       Impact factor: 15.336

9.  Opioid Dose- and Route-Dependent Efficacy of Oxycodone and Heroin Vaccines in Rats.

Authors:  Michael D Raleigh; Megan Laudenbach; Federico Baruffaldi; Samantha J Peterson; Michaela J Roslawski; Angela K Birnbaum; F Ivy Carroll; Scott P Runyon; Scott Winston; Paul R Pentel; Marco Pravetoni
Journal:  J Pharmacol Exp Ther       Date:  2018-03-13       Impact factor: 4.030

10.  Efficacious Vaccine against Heroin Contaminated with Fentanyl.

Authors:  Candy S Hwang; Lauren C Smith; Yoshihiro Natori; Beverly Ellis; Bin Zhou; Kim D Janda
Journal:  ACS Chem Neurosci       Date:  2018-03-23       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.